TY - JOUR T1 - Population Impact and Efficiency of Improvements to HIV PrEP Under Conditions of High ART Coverage among San Francisco Men Who Have Sex with Men JF - medRxiv DO - 10.1101/2021.03.11.21253406 SP - 2021.03.11.21253406 AU - Adrien Le Guillou AU - Susan Buchbinder AU - Hyman Scott AU - Albert Liu AU - Diane Havlir AU - Susan Scheer AU - Samuel M. Jenness Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/12/2021.03.11.21253406.abstract N2 - Background Key components of Ending the HIV Epidemic (EHE) plan include increasing HIV antiretroviral therapy (ART) and HIV preexposure prophylaxis (PrEP) coverage. One complication to addressing this service delivery challenge is the wide heterogeneity of HIV burden and healthcare access across the U.S. It is unclear how the effectiveness and efficiency of expanded PrEP will depend on different baseline ART coverage.Methods We used a network-based model of HIV transmission for men who have sex with men (MSM) in San Francisco. Model scenarios increased varying levels of PrEP coverage relative under current empirical levels of baseline ART coverage and two counterfactual levels. We assessed the effectiveness of PrEP with the cumulative percent of infections averted (PIA) over the next decade and efficiency with the number needed to treat (NNT) by PrEP required to avert one HIV infection.Results In our projections, only the highest levels of combined PrEP and ART coverage achieved the EHE goals. Increasing PrEP coverage up to 75% showed that PrEP effectiveness was higher at higher baseline ART coverage with the PIA ranging from 61% in the lowest baseline ART coverage population to 75% in the highest ART coverage. The efficiency declined with increasing ART (NNT range from 41 to 113).Conclusions Improving both PrEP and ART coverage would have a synergistic impact on HIV prevention even in a high baseline coverage city like San Francisco. Efforts should focus on narrowing the implementation gaps to achieve higher levels of PrEP retention and ART sustained viral suppression.Competing Interest StatementAlbert Liu has received funding for investigator sponsored research grants from Gilead Sciences and Viiv Healthcare, and he has led studies in which Gilead Sciences has donated study drug.Funding StatementThis work was supported by National Institutes of Health grants R21 MH112449 and R01 AI138783.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Emory University Institutional Review Board approved the human subjects research component of the ARTnet and AMIS studies that generated primary data for use in this model.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesModel code and data are available at the Github repositories linked in the Supplemental Appendix document. https://github.com/EpiModel/SFO_PrEP ER -